|
1
|
Mendes V, Dos Santos GO, Calasans-Maia MD, Granjeiro JM, Moraschini V. Impact of bisphosphonate therapy on dental implant outcomes: An overview of systematic review evidence. Int J Oral Maxillofac Surg 2019; 48:373-381. [PMID: 30314708 DOI: 10.1016/j.ijom.2018.09.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Revised: 09/15/2018] [Accepted: 09/21/2018] [Indexed: 10/28/2022]
Abstract
The purpose of this overview was to assess the methods, quality, and outcomes of systematic reviews conducted to evaluate the impact of bisphosphonates on dental implants and the risk of developing bisphosphonate-related osteonecrosis of the jaw after dental implant surgery. An electronic search without date or language restriction was performed in the PubMed/MEDLINE, Cochrane CENTRAL, Web of Science, and LILACS databases (to January 2018). Eligibility criteria included systematic reviews that evaluated the impact of bisphosphonates on implant outcomes. The quality assessment of the included reviews was done using AMSTAR 2 guidelines. The protocol of this overview was registered in PROSPERO (CRD42018089617). The search and selection process yielded seven reviews, published between 2009 and 2017. None of the systematic reviews included in this study obtained the maximum score in the quality assessment. The scientific evidence available demonstrates that patients with a history of bisphosphonate use do not present a higher risk of dental implant failure or marginal bone loss compared to patients who have not used bisphosphonates. The literature also suggests that patients who undergo surgical trauma during the installation of dental implants may be more susceptible to bisphosphonate-related osteonecrosis of the jaw.
Collapse
Affiliation(s)
- V Mendes
- Department of Integrated Clinics, School of Dentistry, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil
| | - G O Dos Santos
- Department of Integrated Clinics, School of Dentistry, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil
| | - M D Calasans-Maia
- Department of Oral Surgery, School of Dentistry, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil
| | - J M Granjeiro
- National Institute of Metrology, Quality and Technology, Rio de Janeiro, Brazil; Cell Therapy Centre, Clinical Research Unit and Department of Dental Techniques, School of Dentistry, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil
| | - V Moraschini
- Department of Periodontology, School of Dentistry, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil.
| |
Collapse
|
|
2
|
Sun Y, Guan Z, Liao M, Yu X, Wang C, Wang J, Niu X, Shi Y, Zhi X, Liu Y, Liu M, Zhang Y, Yang Y, Shen J, Chen G, Zhou Q, Zhou C, Guo Q, Tang L, Duan J, Liang J, Zhang Y, Cheng Y. [Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2014; 17:57-72. [PMID: 24581154 PMCID: PMC6000054 DOI: 10.3779/j.issn.1009-3419.2014.02.01] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Yan Sun
- Cancer Hospital, Chinese Aacademy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Zhongzhen Guan
- SunYat-Sen University Cancer Center,Guangzhou 510060, China
| | - Meilin Liao
- Shanghai Chest Hospital, Shanghai, 200030, China
| | - Xin Yu
- Department of psychiatry, Peking University Sixth Hospital, Beijing 100191, China
| | - Changli Wang
- Department of Lung Cancer Surgery, Tianjin Cancer Hospital, Tianjin 300060, China
| | - Jie Wang
- Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Peking University, Beijing 100142, China
| | - Xiaohui Niu
- Department of Orthopedic Oncology Surgery, Beijing Jishuitan Hospital, Beijing 100035, China
| | - Yuankai Shi
- Department of Medical Oncology, Cancer Hospital, Chinese Aacademy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Xiuyi Zhi
- Department of Thoracic Surgery, Beijing Lung Cancer Center, Beijing Xuanwu Hospital, Capital Medical University, Beijing 100053, China
| | - Yunpeng Liu
- Departmentof Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China
| | - Mengzhong Liu
- Department of Radiotherapy, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
| | - Yiping Zhang
- Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China
| | - Yue Yang
- Department of Thoracic Surgery, Beijing Cancer Hospital, Peking University, Beijing 100142, China
| | - Jingnan Shen
- Department of Orthopedic Oncology Surgery, the First Affiliated Hospital Sun Yat-Sen University, Guangzhou 510080, China
| | - Gongyan Chen
- Department of Medical Oncology, Haerbin Medical University Cancer Hospital, Haerbin 150081, China
| | - Qinghua Zhou
- Department of Thoracic Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Caicun Zhou
- Departmentof Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China
| | - Qisen Guo
- Department of Medical Oncology, Shandong Province cancer Hospital, Jinan 250117, China
| | - Lili Tang
- Department of rehabilitation, Beijing Cancer Hospital, Peking University, Beijing 100142, China
| | - Jianchun Duan
- Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Peking University, Beijing 100142, China
| | - Jun Liang
- Department of Medical Oncology, the Affiated Hospital of Qingdao University, Qingdao 266003, China
| | - Yingjian Zhang
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China
| | - Ying Cheng
- Department of Medical Oncology, Jilin Cancer Hospital, Changchun 130012, China
| |
Collapse
|
|
3
|
Terpos E, Sezer O, Croucher P, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20:1303-17. [DOI: 10.1093/annonc/mdn796] [Citation(s) in RCA: 179] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
|
|
4
|
DELGUSTE C, AMORY H, GUYONNET J, THIBAUD D, GARNERO P, DETILLEUX J, LEPAGE OM, DOUCET M. Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1. J Vet Pharmacol Ther 2008; 31:108-16. [DOI: 10.1111/j.1365-2885.2007.00936.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
|
5
|
Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and Gastrointestinal Tolerability of Monthly Oral or Quarterly Intravenous Ibandronate Therapy in Women with Previous Intolerance to Oral Bisphosphonates: A 12-Month, Open-Label, Prospective Evaluation. Clin Ther 2008; 30:605-21. [DOI: 10.1016/j.clinthera.2008.04.009] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/02/2008] [Indexed: 10/22/2022]
|
|
6
|
Finkel KW, Foringer JR. Renal disease in patients with cancer. ACTA ACUST UNITED AC 2008; 3:669-78. [PMID: 18033226 DOI: 10.1038/ncpneph0622] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2006] [Accepted: 06/29/2007] [Indexed: 01/08/2023]
Abstract
Kidney disease is very common in patients with cancer. Nephrologists are vital members of the multidisciplinary care team for these patients. Given the high prevalence of comorbidities in patients treated for active malignancy, it is not surprising that these individuals frequently develop renal diseases that are common among other hospitalized patients, such as those arising from sepsis, hypotension or use of nephrotoxic agents (e.g. radiocontrast or antimicrobial agents). The role of the nephrologist in these cases differs little with respect to the presence or absence of cancer. On the other hand, there are several renal syndromes that are unique to patients with cancer, being caused either by the cancer itself or by its treatment. These syndromes are reviewed here. In addition, patients who are receiving chemotherapy often require dialysis for either acute or chronic kidney disease. Unfortunately, there is very little information on the clearance characteristics of most chemotherapeutic agents. In cancer patients with renal disease, both the timing of administration and the dose-adjustment of chemotherapy must rely on clinical experience and close clinical observation.
Collapse
Affiliation(s)
- Kevin W Finkel
- Division of Renal Diseases and Hypertension, University of Texas Medical School at Houston, Houston, TX 77030, USA.
| | | |
Collapse
|